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The first sentence in many articles on systemic sclerosis
reads something like this: Bsystemic sclerosis is a rare, autoim-
mune connective tissue disease of unknown origin affecting the
skin and visceral organs, which leads to excess morbidity and
premature mortality. Its pathogenesis is characterized by vascu-
lopathy, activation of the immune system and fibrosis.^ While
these words are true, they ignore the complexity of the biology
and the variability in clinical expressions of systemic sclerosis,
reflecting a heterogeneous condition. Perhaps systemic sclero-
sis is better viewed as a syndrome comparable to glomerulone-
phritis or rheumatoid arthritis rather than a simple disease such
as the flu. The present volume on the immunopathology of
systemic sclerosis provides ample support for this notion. This
is driven, in part, by the advent of unprecedented powerful new
laboratory techniques which enable genome-wide association
studies, gene-expression studies in blood and skin, multiparam-
eter flow cytometric analyses of cell subsets, proteomics, etc.,
generating a wealth of data, the analysis of which requires
specialist bioinformatic approaches. Yet a sharper focus on
the biological processes driving systemic sclerosis is essential
if we are to succeed in developing more targeted, hence more
effective therapies that result in better outcomes of patients.
Fortunately, the past few years have witnessed major prog-
ress in our understanding of the immunopathology of systemic
sclerosis, as illustrated by several high-profile publications in
the top medical journals [1, 2]. One particularly intriguing
theory about the immunological cross-reactivity between ma-
lignancy and anti-RNA polymerase III positive systemic scle-
rosis has come to the fore [1]. According to this theory, ma-
lignant cells evoke an immune response as part of a host’s
defense to clear the malignant cells. This then may be accom-
panied by an autoimmune response against specific nuclear
antigens present in the malignant cells, which triggers specific
autoantibody formation and—somehow—activates other
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systemic sclerosis pathways, although this part of the story
remains to be told. The tight temporary relationship between
the malignancy and systemic sclerosis in such cases is sugges-
tive of a common disease mechanism and is in line with other
reported epidemiological data indicating a link between ma-
lignancy and systemic sclerosis [3, 4]. Autoimmunity may be
the price an individual pays to mount an effective anti-tumor
response. While this theory has strong appeal, it will be diffi-
cult, if not impossible, to prove how this mechanism applies to
all cases of SSc, e.g., in SSc patients who do not develop overt
malignancy. In the majority of cases, therefore, we remain
stuck with the old paradigm that systemic sclerosis just like
any other autoimmune disease develops in an (epi)genetically
predisposed individual for unknown reasons in the absence of
a demonstrable trigger.
Yet these gaps in our understanding of the key decision
points involved in disease progression can not obscure the
lessons we have learned from meticulously analyzing the
aforementioned pathogenetic pathways of systemic sclerosis
and (epi)genetic factors. A number of key molecules (eg
endothelin-1) involved in vasculopathy have been identified
and several targeted therapies are in routine clinical use. As a
result pulmonary arterial hypertension (PAH), a previously
uniformly fatal complication of systemic sclerosis, has be-
come a treatable chronic condition, although much remains
to be learned about the factors driving its progression. Simi-
larly, while it has long been known that innate and acquired
immune abnormalities play a role in systemic sclerosis, accu-
mulating data from studies in animal models of inflammation-
driven fibrosis and translational research in systemic sclerosis
patients have led to a wealth of new therapeutic targets and a
flurry of clinical trials. While proof-of-concept trials are a
critical step in drug development, ultimately large-scale con-
trolled, randomized trials are necessary to provide the clinical
evidence for a drug (or any treatment really) to be shown safe
and effective. The history of clinical trials in systemic sclero-
sis, however, is littered with the carcasses of once promising
drugs; think of relaxin, oral collagen, D-penicillamine,
imatinib.
We believe that the tide has now turned, and recently com-
pleted clinical studies point to better times ahead. An analysis
of rituximab-treated systemic sclerosis patients from the Eu-
ropean Scleroderma Trial and Research (EUSTAR) registry
provided a strong suggestion that B-cell depletion is a valid
treatment target [5]. There is a solid scientific rationale for
targeting B cells, not only as progenitors of plasma cells which
mediate autoantibody production but also as a source of pro-
inflammatory cytokines, and actors in antigen presentation.
The placebo-controlled phase-2 FASSCINATE trial provided
tantalizing data indicating that the prolonged use of toci-
lizumab may slow down lung and skin disease in patients with
early diffuse cutaneous systemic sclerosis [6]. It is hoped that
these results can be confirmed in a pivotal phase 3 trial.
Interleukin-6 is produced by many cell types implicated in
the pathogenesis of systemic sclerosis, including monocytes,
endothelial cells, fibroblasts, and B- and T-lymphocytes, is
expressed in affected skin in early diffuse cutaneous systemic
sclerosis and has profibrotic effects. Serum concentrations
have been shown to correlate with the extent of skin thicken-
ing and long-term outcome [7]. If confirmed, the beneficial
effects of IL-6 neutralization in early diffuse cutaneous sys-
temic sclerosis would underscore a key assumption of its enig-
matic pathogenesis, namely that fibrogenesis in certain pa-
tients can be disrupted by profound suppression of systemic
inflammation. Support for this notion also came from evi-
dence garnered in a recent open-label clinical trial in 15 pa-
tients with early diffuse cutaneous systemic sclerosis with a
neutralizing antibody against all TGF-ß isoforms. This study
showed significant reduction of TGF-ß regulated genes
paralleled by an equally rapid and strong improvement of skin
thickening [8]. A small placebo-controlled clinical trial with
abatacept showed that clinical improvement was associated
with modulation of inflammatory pathways in skin [9]. Fur-
ther large-scale clinical trials with these biologics are needed
to confirm their clinical utility and determine the appropriate
role of patient stratification.
Perhaps the most compelling evidence for the pathogenic
role of systemic inflammation in SSc fibrogenesis so far has
come from the international phase-3 ASTIS-trial of 156 pa-
tients with early diffuse cutaneous systemic sclerosis who
were randomized to treatment with either autologous hemato-
poietic stem cell transplantation (HSCT) or monthly intrave-
nous pulse cyclophosphamide [10]. With a median follow-up
of 5.8 years, the HSCT-treated group showed improved long-
term survival, a more rapid and profound improvement of skin
thickening, lung function, and quality of life after 2 years,
pointing to disease-modifying effects of intensive immuno-
suppression in poor-prognosis patients.
A main lesson from these clinical trials is that enrichment
for patients with early diffuse cutaneous systemic sclerosis is
a critical design element in proof-of-concept trials with
drugs or biologics targeting immune cells or molecules,
and that such trials should be accompanied by a comprehen-
sive analysis of biomarkers and patient and disease charac-
teristics. Notwithstanding the encouraging outcomes of re-
cent clinical trials, much remains to be learned about the
nature of the interactions between vasculopathy, inflamma-
tion, and fibrosis, and their variable roles in the different
patient subsets encompassing the systemic sclerosis spec-
trum. New technologies are already proving useful in this
respect [11].
The present volume hopes to fill the voids with a series
of state-of-the-art reviews on different aspects of the immu-
nopathology of systemic sclerosis authored by leading au-
thorities. Taken together, they paint a picture of a great
work in progress.
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